Skip to content

The effect of Basilic phlebotomy on sciatalgia and its comparison with classical medical treatment

The effect of Basilic phlebotomy on sciatalgia and its comparison with classical medical treatment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180131038575N1
Enrollment
50
Registered
2018-02-27
Start date
2018-02-20
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sciatica pain. Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention 1: Intervention group: phlebotomy. Intervention 2: Control group: Taking 50 to 100 mg of diclofenac tablets based on patient weight (less than 60 kg), Alborz Medication will be placed twi

Sponsors

Shahed University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Sciatica pain requires non-surgical treatment 35 > BMI >18 Fixed weight The desire to participate in a patient's study There is no history of surgical dislocations of the spine and severe sensory and motor pain Inflammatory back pain, rheumatism, ganglion and metabolic disorders, bad breaths, blood diseases and coagulation diseases, and pelvic abnormalities due to CDH or other spinal diseases such as scoliosis, kyphosis, spondylolisthesis, etc. Do not have anemia Not being treated with morphine or drug addiction Pregnant or lactating women. There is no history of fracture or surgery in the last three months. There is no history of any inflammatory disease of the joints, such as rheumatoid arthritis, rheumatic fever, and ankylosing spondylitis. The patient should not be cold and dry in a less than warm, dry environment No significant mental illness (such as schizophrenia). Do not stop taking Diclofenac tablets Not being treated with anticoagulants

Exclusion criteria

Exclusion criteria: Possible side effects of treatment Unwillingness to continue to participate in the plan. Irreparable aggravation of pain and disability.

Design outcomes

Primary

MeasureTime frame
Intensity of pain. Timepoint: Before, one day, three days, ten days and four weeks after the scheduled time. Method of measurement: VAS questionnaire.

Secondary

MeasureTime frame
Quality of Life. Timepoint: Before the start of the project and one month later (the end of the project). Method of measurement: SF36 questionnaire.;Disability. Timepoint: Before the start of the project and one month later (the end of the project). Method of measurement: Ronaldomiris questionnaire.;Generic temper. Timepoint: Before the start of the project and one month later (the end of the project). Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hasan Amini

Shahed University

mhassan.amini@shahed.ac.ir+98 21 51210

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026